Imatinib Ratiopharm

Imatinib, the active ingredient in Imatinib Ratiopharm, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Imatinib targets abnormal tyrosine‑kinase signaling in several hematologic and solid tumours. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable molecular remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction and maintenance in combination regimens. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and improves progression‑free survival in patients with KIT or PDGFRA mutations.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Edema: peripheral swelling, especially of the ankles. - Fatigue: generalized tiredness. - Muscle cramps: occasional skeletal muscle discomfort. - Rash: mild skin eruption.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: reduced left ventricular ejection fraction or heart failure. - Severe neutropenia: marked decrease in neutrophil count. - Hemorrhage: increased risk of bleeding events. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Interstitial lung disease: rare pulmonary inflammation.

When prescribing Imatinib, clinicians should consider several safety and handling precautions. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Assess cardiac status: evaluate ejection fraction before and during therapy. - Check blood counts: regular CBC to detect neutropenia or anemia. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Counsel on potential drug interactions: review concomitant medications for CYP3A4 substrates. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Imatinib can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption, consider timing adjustments. - Concomitant anticoagulants (e.g., warfarin): increased bleeding risk, monitor INR. - Live attenuated vaccines: potential reduced efficacy, assess risk‑benefit.